Mini Review

Published on 17 Jan 2022

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

in Cancer Molecular Targets and Therapeutics

Luyao Wang
Yurong Chen
Xinrui Liu
Ziyi Li
Xiangpeng Dai

Frontiers in Oncology

doi 10.3389/fonc.2021.704999

12,649 views
18 citations

Review

Published on 12 Jan 2022

Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway

in Cancer Molecular Targets and Therapeutics

Yusheng Guo
Guohui Wu
Junrong Yi
Qin Yang
Wengong Jiang
Shaoqiang Lin
Xiaorong Yang
Xiangsheng Cai
Liufeng Mao

Frontiers in Oncology

doi 10.3389/fonc.2021.763539

4,924 views
16 citations

Review

Published on 11 Jan 2022

Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis

in Cancer Molecular Targets and Therapeutics

Ting Wen
Qiao Yi Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.806974

4,365 views
6 citations

Original Research

Published on 10 Jan 2022

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population

in Cancer Molecular Targets and Therapeutics

Yajun Wang
Lan Yao
Yao Teng
Hua Yin
Qiuling Wu

Frontiers in Oncology

doi 10.3389/fonc.2021.783583

3,224 views
7 citations

Correction

Published on 07 Jan 2022

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

in Cancer Molecular Targets and Therapeutics

Fang Wei
Mofei Wang
Zhen Li
Yong Wang
Yong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.818876

1,542 views

Original Research

Published on 07 Jan 2022

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

in Cancer Molecular Targets and Therapeutics

Michael S. Gordon
Geoffrey I. Shapiro
John Sarantopoulos
Dejan Juric
Brian Lu
Angeliki Zarotiadou
Jamie N. Connarn
Yvan Le Bruchec
Calin Dan Dumitru
R. Donald Harvey

Frontiers in Oncology

doi 10.3389/fonc.2021.786120

3,002 views
11 citations

Mini Review

Published on 07 Jan 2022

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

in Cancer Molecular Targets and Therapeutics

Farbod Shojaei
Bob Goodenow
Gloria Lee
Fairooz Kabbinavar
Mireille Gillings

Frontiers in Oncology

doi 10.3389/fonc.2021.768685

5,045 views
2 citations

Clinical Trial

Published on 07 Jan 2022

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

in Cancer Molecular Targets and Therapeutics

Ryunosuke Nakagawa
Hiroaki Iwamoto
Tomoyuki Makino
Suguru Kadomoto
Hiroshi Yaegashi
Masashi Iijima
Shohei Kawaguchi
Takahiro Nohara
Kazuyoshi Shigehara
Kouji Izumi

Frontiers in Oncology

doi 10.3389/fonc.2021.770067

6,441 views
5 citations

Original Research

Published on 06 Jan 2022

Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation

in Cancer Molecular Targets and Therapeutics

Huihui Ji
Kehan Li
Wenbin Xu
Ruyi Li
Shangdan Xie
Xueqiong Zhu

Frontiers in Oncology

doi 10.3389/fonc.2021.780387

5,116 views
18 citations

Review

Published on 06 Jan 2022

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

in Cancer Molecular Targets and Therapeutics

Timothy A. Yap
Ira Jacobs
Elodie Baumfeld Andre
Lauren J. Lee
Darrin Beaupre
Laurent Azoulay

Frontiers in Oncology

doi 10.3389/fonc.2021.695936

13,008 views
29 citations

Original Research

Published on 06 Jan 2022

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

in Cancer Molecular Targets and Therapeutics

Massimiliano Bonifacio
Cristina Papayannidis
Federico Lussana
Nicola Fracchiolla
Mario Annunziata
Simona Sica
Mario Delia
Robin Foà
Giovanni Pizzolo
Sabina Chiaretti

Frontiers in Oncology

doi 10.3389/fonc.2021.804714

4,464 views
14 citations

Review

Published on 06 Jan 2022

Crosstalk Among YAP, LncRNA, and Tumor-Associated Macrophages in Tumorigenesis Development

in Cancer Molecular Targets and Therapeutics

Jing Xu
Xin-Yuan Liu
Qi Zhang
Hua Liu
Peng Zhang
Zi-Bin Tian
Cui-Ping Zhang
Xiao-Yu Li

Frontiers in Oncology

doi 10.3389/fonc.2021.810893

4,589 views
13 citations

Systematic Review

Published on 05 Jan 2022

Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials

in Cancer Molecular Targets and Therapeutics

Jiawei Zhou
Jianling Bai
Yuanping Yue
Xin Chen
Theis Lange
Dongfang You
Yang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2021.757456

3,292 views
2 citations

Original Research

Published on 05 Jan 2022

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma

in Cancer Molecular Targets and Therapeutics

Yafei Wang
Lin Chen
Qian Li
Shuang Gao
Su Liu
Jing Ma
Ying Xie
Jingya Wang
Zeng Cao
Zhiqiang Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.785297

2,206 views
6 citations

Original Research

Published on 03 Jan 2022

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas

in Cancer Molecular Targets and Therapeutics

Zhichao Liao
Chao Zhang
Tielong Yang
Haotian Liu
Songwei Yang
Ting Li
Ruwei Xing
Sheng Teng
Yun Yang
Jun Zhao

Frontiers in Oncology

doi 10.3389/fonc.2021.778774

2,018 views
2 citations

Retraction

Published on 29 Dec 2021

Retraction: Downregulation of hsa_circ_0001836 Induces Pyroptosis Cell Death in Glioma Cells via Epigenetically Upregulating NLRP1

in Cancer Molecular Targets and Therapeutics

Frontiers Editorial Office

Frontiers in Oncology

doi 10.3389/fonc.2021.840877

3,877 views
1 citation

Navigation group

Articles

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway

Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Crosstalk Among YAP, LncRNA, and Tumor-Associated Macrophages in Tumorigenesis Development

Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas

Retraction: Downregulation of hsa_circ_0001836 Induces Pyroptosis Cell Death in Glioma Cells via Epigenetically Upregulating NLRP1